Current situation of hepatitis C in USA

- ✓ Prevalence: Approx 1.5%, may be underestimate
- ✓ Total number of patients: 3.2-5 million
- ✓ Mortality: 20,000 deaths from HCV in U.S. (2014)
- ✓ Number of liver transplantations: ~1000/year
- Total number of patients treated by DAAs
 - ✓ Approx 650,000 treated during 2015-217
- Total number of patients treated by DAAs by year
 - ✓ 2015: 255K 2016: 218K 2017: 180K

Current ressources and programs for HCV

- Current resources provided by Health Authorities (amount in euros/year): No fixed amount is designated by federal government Treatment eligibility is determined by multiple different payers. Each payer has individual guidelines for treatment
- DAAs available: All that are still on the market
- Program for screening: Baby Boomer supplemented by riskbased screening is recommended, but not mandated

 Program to improve access to treatment: Grass roots efforts to expand treatment to primary care providers

Future actions planned

✓ To improve screening: « Action Plan to Eradicate Viral Hepatitis » has been endorsed: No funding mechanism identified

- ✓ To facilitate access to treatment: Expand treatment to PCPs, Focus on treating PWIDs.
- ✓ Future drugs available: None likely

Other major action: Treat Opiate Epidemic